Bank of America just raised its EUR/USD forecast
Allison C. Hoffman, the General Counsel and Secretary of Phreesia, Inc. (NYSE:PHR), recently sold a portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Hoffman sold 3,496 shares of Phreesia’s common stock on March 17, 2025. The shares were sold at an average price of $25.32, amounting to a total transaction value of $88,518. Since then, the stock has rallied to $29, near its 52-week high of $30.53, posting an impressive 14.6% gain in the past week. InvestingPro analysis shows analysts maintain a strong buy consensus with price targets ranging from $29 to $36.
Following this sale, Hoffman’s direct ownership of Phreesia stock stands at 139,134 shares. This transaction was carried out under a pre-arranged Rule 10b5-1 trading plan, which Hoffman adopted on September 17, 2024. The $1.71 billion healthcare technology company maintains a GREAT financial health score according to InvestingPro, which offers comprehensive analysis and additional insights through its detailed Pro Research Report, available for over 1,400 US stocks.
In other recent news, Phreesia Inc . has been the focus of multiple analyst updates following its fourth-quarter earnings report. Jefferies raised its price target for Phreesia from $28.00 to $32.00, maintaining a Buy rating due to the company’s operational leverage and strategic shift towards Network Solutions. KeyBanc Capital Markets also reiterated an Overweight rating with a $30.00 target, noting significant margin improvements and strong top-line growth. Similarly, Raymond (NSE:RYMD) James maintained an Outperform rating with a $30.00 price target, emphasizing Phreesia’s transition to a focus on free cash flow and profitability.
DA Davidson reaffirmed a Buy rating with a $36.00 target, highlighting Phreesia’s undervalued stock and consistent performance in the U.S. healthcare services sector. Canaccord Genuity increased its price target to $35.00, citing Phreesia’s expanded margins and positive cash flow profile. The company reported an adjusted EBITDA of $36.8 million, marking its first year of positive adjusted EBITDA since FY’21. Phreesia’s Gross Profit Margin on Subscription and Network revenue reached 80.6%, reflecting a significant year-over-year increase.
The company is noted for its involvement in 14% of all doctor visits in the U.S., providing a unique platform for patient engagement and marketing campaigns. Phreesia’s strategic initiatives, including the launch of new products like Appointment Readiness, are anticipated to enhance patient interaction further. Analysts express confidence in Phreesia’s growth trajectory and financial performance, with expectations for continued improvements in margins and cash flow.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.